机构

• 上海药物研究所 [35]
• 合肥物质科学研究院 [13]
• 金属研究所 [2]
• 海洋研究所 [1]
• 上海生物化学与细胞生... [1]

采集方式

• OAI收割 [52]

内容类型

• 期刊论文 [52]

发表日期

• 2024 [1]
• 2023 [2]
• 2022 [5]
• 2021 [8]
• 2020 [7]
• 2019 [2]
• 更多

学科主题

• Pharmacolo... [1]

筛选

浏览/检索结果: 共52条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序发表日期升序发表日期降序题名升序题名降序作者升序作者降序 JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers 期刊论文  OAI收割 CANCER LETTERS, 2024, 卷号: 582, 页码: 15 作者:  Lu, Xuxiu;  Yu, Rilei;  Li, Zhen;  Yang, Mengke;  Dai, Jiajia   |  收藏  |  浏览/下载：13/0  |  提交时间：2024/04/07 Acquired resistance  Cancer  NSCLC  JC-010a  SHP2   Synthesis, and biological evaluation of EGFR/HER2-NAMPT conjugates for tumor treatment 期刊论文  OAI收割 MOLECULAR DIVERSITY, 2023, 页码: 20 作者:  Ding, Mengyuan;  Shen, Qianqian;  Lu, Wei;  Zhu, Shulei   |  收藏  |  浏览/下载：62/0  |  提交时间：2023/10/17 EGFR  HER2  NAMPT  Resistance  Selectivity  Molecular docking   Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo 期刊论文  OAI收割 JOURNAL OF CANCER, 2023, 卷号: 14, 期号: 1, 页码: 152-162 作者:  Lai, Mengzhen;  Zhang, Tao;  Chen, Hao;  Song, Peiran;  Tong, Linjiang   |  收藏  |  浏览/下载：80/0  |  提交时间：2023/04/10 fourth-generation EGFR inhibitor  EGFRC797S mutation  NSCLC  drug resistance  small molecular inhibitor   Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib 期刊论文  OAI收割 BMC CANCER, 2022, 卷号: 22 作者:  Jin, Ying;  Lin, Chen;  Shi, Xun;  He, Qiong;  Yan, Junrong   |  收藏  |  浏览/下载：71/0  |  提交时间：2022/12/23 Clinical and molecular features  Efficacy and outcome  EGFR T790M mutation  Non-small-cell lung cancer  Osimertinib   Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-GenerationEpidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations br 期刊论文  OAI收割 JOURNAL OF MEDICINAL CHEMISTRY, 2022, 卷号: 65, 期号: 9, 页码: 6840-6858 作者:  Chen, Hao;  Lai, Mengzhen;  Zhang, Tao;  Chen, Yuqing;  Tong, Linjiang   |  收藏  |  浏览/下载：23/0  |  提交时间：2022/08/16 Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-GenerationEpidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations 期刊论文  OAI收割 JOURNAL OF MEDICINAL CHEMISTRY, 2022, 卷号: 65, 期号: 9, 页码: 6840-6858 作者:  Chen, Hao;  Lai, Mengzhen;  Zhang, Tao;  Chen, Yuqing;  Tong, Linjiang   |  收藏  |  浏览/下载：6/0  |  提交时间：2024/03/21 Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting Del19/T790M/C797S Mutation 期刊论文  OAI收割 ACS MEDICINAL CHEMISTRY LETTERS, 2022, 卷号: 13, 期号: 2, 页码: 278-283 作者:  Zhang, Hualin;  Xie, Ruliang;  AI-furas, Hawaa;  Li, Yupeng;  Wu, Qingxia   |  收藏  |  浏览/下载：26/0  |  提交时间：2022/06/15 NSCLC  acquired resistance  EGFR C797S  PROTACs  selectivity   Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR(T790M/C797S) Mutants 期刊论文  OAI收割 ACS MEDICINAL CHEMISTRY LETTERS, 2022, 页码: 7 作者:  Li, Shan;  Zhang, Tao;  Zhu, Su-Jie;  Lei, Chong;  Lai, Mengzhen   |  收藏  |  浏览/下载：25/0  |  提交时间：2022/06/15 Epidermal Growth Factor Receptor (EGFR)  Resistant Mutation  C797S  Antitumor   LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo 期刊论文  OAI收割 CANCER SCIENCE, 2021, 页码: 12 作者:  Liu, Yingqiang;  Lai, Mengzhen;  Li, Shan;  Wang, Yanan;  Feng, Fang   |  收藏  |  浏览/下载：87/0  |  提交时间：2022/01/18 C797S  epidermal growth factor receptor  fourth-generation EGFR TKI  non-small cell lung cancer  osimertinib resistance   Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs) 期刊论文  OAI收割 ANNALS OF PALLIATIVE MEDICINE, 2021 作者:  Si, Jinfei;  Gu, Xiaodong;  Wang, Wenxian;  Ying, Shenpeng;  Song, Zhengbo   |  收藏  |  浏览/下载：78/0  |  提交时间：2022/02/14 Epidermal growth factor receptor (EGFR)  uncommon mutation  compound mutation  double uncommon mutation  lung adenocarcinoma (lung AC)